What is Massive Bio?
Massive Bio operates at the intersection of artificial intelligence and oncology, aiming to democratize access to clinical trials for cancer patients globally. The company's AI-driven platform meticulously matches patients with suitable clinical trials, addressing geographical and financial barriers. By controlling the patient enrollment value chain, from identification to virtual pre-screening, Massive Bio accelerates drug development for over two dozen pharmaceutical companies, contract research organizations (CROs), and hospital networks. Their services encompass oncology-dedicated patient recruitment, site selection, real-world data services, and AI-based trial prescreening, positioning them as a key enabler in the modern healthcare ecosystem.
How much funding has Massive Bio raised?
Massive Bio has raised a total of $11.7M across 3 funding rounds:
Other Financing Round
$2.6M
Debt
$74K
Other Financing Round
$9M
Other Financing Round (2020): $2.6M with participation from Cavendish Impact Foundation and Revo Capital
Debt (2021): $74K led by PPP
Other Financing Round (2022): $9M supported by Revo Capital
Key Investors in Massive Bio
Revo Capital
Revo Capital is a venture capital firm that invests in innovative, early-stage B2B and B2C technology ventures primarily in Turkey, Eastern Europe, and the Baltics. The firm aims to empower local entrepreneurs to unlock their global potential by providing financial backing and strategic support.
PPP
Public-Private Partnership
Cavendish Impact Foundation
Undisclosed investor participating in the funding round.
What's next for Massive Bio?
With its recent major strategic investment, Massive Bio is poised for accelerated growth and enhanced service delivery. The company's focus on leveraging AI to bridge the gap in clinical trial access for cancer patients aligns with the increasing demand for efficient and equitable healthcare solutions. Future initiatives are likely to involve expanding their platform's capabilities, forging new partnerships with healthcare providers and pharmaceutical entities, and further developing their AI algorithms to refine patient-trial matching accuracy. This strategic capital infusion will be instrumental in scaling their operations, solidifying their market position, and ultimately contributing to faster, more effective cancer treatment development.
See full Massive Bio company page
